It Looks Like C4 Therapeutics, Inc.'s (NASDAQ:CCCC) CEO May Expect Their Salary To Be Put Under The Microscope

By Yahoo! Finance | Jun 14, 2024 at 08:16 AM EST

C4 Therapeutics' disappointing 87% shareholder loss and 2.9% EPS decline over three years will likely concern investors. CEO compensation, although in line with industry standards, is being questioned due to poor company performance. Shareholders seek improvement and accountability at the upcoming AGM.

Did you find this insightful?

Bad

Just Okay

Amazing

We are preparing, please wait

New Alert

Select an alert type

Sentiment Spike

Send email alert if news sentiment changes significantly

Mentions Spike

Send email alert if has a surge in mentions

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.